peipe	concy.
It is made available under a CC	C-BY 4.0 International license

1	Levels of SARS-CoV-2 population exposure are considerably higher than
2	suggested by seroprevalence surveys
3	Authors: Siyu Chen ¹ , Jennifer A Flegg ² , Lisa J White ¹ , Ricardo Aguas ^{3*}
4	Affiliations:
5	¹ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department
6	of Medicine, University of Oxford.
7	² School of Mathematics and Statistics, University of Melbourne, Melbourne, Australia.
8	³ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
9	Oxford, Oxford, United Kingdom.
10	*Correspondence to: ricardo@tropmedres.ac

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

11 Abstract

12 Accurate knowledge of accurate levels of prior population exposure has critical ramifications for preparedness plans of subsequent SARS-CoV-2 epidemic waves and vaccine prioritization strategies. 13 Serological studies can be used to estimate levels of past exposure and thus position populations in 14 their epidemic timeline. To circumvent biases introduced by decaying antibody titers over time, 15 population exposure estimation methods should account for seroreversion, to reflect that changes in 16 seroprevalence measures over time are the net effect of increases due to recent transmission and 17 decreases due to antibody waning. Here, we present a new method that combines multiple datasets 18 (serology, mortality, and virus positivity ratios) to estimate seroreversion time and infection fatality 19 ratios and simultaneously infer population exposure levels. The results indicate that the average time 20 to seroreversion is six months, and that true exposure may be more than double the current 21 22 seroprevalence levels reported for several regions of England.

23

Key words: SARS-CoV-2; serology; antibody decline; seroreversion; exposure; infection fatality
 ratio

26 Introduction

The COVID-19 pandemic has inflicted devastating effects on global populations and economies¹. 27 Levels and styles of reporting epidemic progress vary considerably across countries², with cases 28 consistently being under-reported and case definitions changing significantly over time. Therefore, 29 the scientific and public health communities turned to serological surveys as a means to position 30 31 populations along their expected epidemic timeline, and thus provide valuable insights into COVID-19 lethality^{3,4}. Those prospects were frustrated by apparent rapid declines in antibody levels 32 following infection⁵⁻⁷. Population wide antibody prevalence measurements can significantly 33 underestimate the amount of underlying population immunity with obvious implications for 34 intervention strategy design and vaccine impact measurement. 35

Continued research efforts to determine the correlates for protective immunity against disease and infection have found that while antibody titers are poor indicators of sustained immunity, cellular immunity can play a determinant role in limiting susceptibility to further SARS-CoV-2 challenges in previously exposed individuals^{8,9}. Unfortunately, performing T cell assays at scale is technically challenging and expensive, which justified the decision to conduct a series of serology surveys (some of which are still underway) in many locations globally to provide a better understanding of the extent of viral spread among populations¹⁰.

In England, a nationwide survey sampling more than 100,000 adults was performed from 20 June to 13 July 2020. The results suggested that 13% and 6% of the population of London and England, respectively, had been exposed to SARS-CoV-2, giving an estimated overall infection fatality ratio (IFR) of 0.90%¹¹. Although corrections were made for the sensitivity and specificity of the test used

to infer seroprevalence, declining antibody levels were not accounted for. This is a limitation of the
approach, potentially resulting in underestimates of the true levels of population exposure¹² and an
overestimate of the IFR.

50

We now have a much clearer picture of the time dynamics of humoral responses following SARS-CoV-2 exposure, with antibody titers remaining detectable for approximately 6 months^{13,14}. Commonly used serological assays have a limit of antibody titer detection, below which a negative result is yielded. Hence, a negative result does not necessarily imply absence of antibodies, but rather that there is a dynamic process by which production of antigen targeted antibodies diminishes once infection has been resolved, resulting in decaying antibody titers over time. As antibody levels decrease beyond the limit of detection, seroreversion occurs.

58

We define the seroreversion rate as the inverse of the average time taken following seroconversion for antibody levels to decline below the cut-off for testing seropositive. In a longitudinal follow-up study, antibodies remained detectable for at least 100 days⁶. In another study¹⁵, seroprevalence declined by 26% in approximately three months, which translates to an average time to seroreversion of around 200 days. However, this was not a cohort study, so newly admitted individuals could have seroconverted while others transitioned from positive to negative between rounds, leading to an overestimation of the time to seroreversion.

Intuitively, if serology were a true measure of past exposure, we would expect a continually 67 increasing prevalence of seropositive individuals over time. However, data suggest this is not the 68 case¹⁶, with most regions in England showing a peak in seroprevalence at the end of May 2020. This 69 suggests seroreversion plays a significant role in shaping the seroprevalence curve and that the time 70 since the first epidemic peak will influence the extent to which subsequent seroprevalence 71 72 measurements underestimate the underlying population attack size (proportion of the population exposed). We argue that the number of people infected during the course of the epidemic can be 73 informed by data triangulation, i.e., by combining numbers of deceased and seropositive individuals 74 over time. For this linkage to be meaningful, we need to carefully consider the typical SARS-CoV-2 75 infection and recovery timeline (Figure 1). 76

77





83

Most individuals, once infected, experience an incubation period of approximately 4.8 days (95% confidence interval (CI): 4.5–5.8)¹⁷, followed by the development of symptoms, including fever, dry

cough, and fatigue, although some individuals will remain asymptomatic throughout. Symptomatic individuals may receive a diagnostic PCR test at any time after symptoms onset; the time lag between symptoms onset and date of test varies by country and area, depending on local policies and testing capacity. Some individuals might, as their illness progresses, require hospitalization, oxygen therapy, or even intensive care, eventually either dying or recovering.

91 The day of symptoms onset, as the first manifestation of infection, is a critical point for identifying when specific events occur relative to each other along the infection timeline. The mean time from 92 symptoms onset to death is estimated to be 17.8 days (95% credible interval (CrI): 16.9-19.2) and to 93 hospital discharge 24.7 days (22.9–28.1)^{18.} The median seroconversion time for IgG (long-lasting 94 antibodies thought to be indicators of prior exposure) is estimated to be 14 days post-symptom onset; 95 the presence of antibodies is detectable in less than 40% of patients within 1 week of symptoms onset, 96 rapidly increasing to 79.8% (IgG) at day 15 post-onset¹⁹. We assume onset of symptoms occurs at 97 98 day 5 post-infection and that it takes an average of 2 additional days for people to have a PCR test. Thus, we fix the time lag between exposure and seroconversion, δ_{ϵ} , at 21 days, the time lag between 99 a PCR test and death, δ_P , as 14 days, and assume that seroconversion in individuals who survive 100 101 occurs at approximately the same time as death for those who don't (Figure 1).

102

Thus, we propose to use population level dynamics (changes in mortality and seroprevalence over time) to estimate three key quantities: the seroreversion rate, the IFR, and the total population exposure over time. We developed a Bayesian inference method to estimate said quantities, based on official epidemiological reports and a time series of serology data from blood donors in England,

stratified by region 16 – see Materials and Methods for more details. This dataset informed the 107 national COVID-19 serological surveillance and its data collection was synchronous with the 108 "REACT" study¹¹. The two sero-surveys use different, but comparable, antibody diagnostic tests²⁰. 109 While "REACT" used a lateral flow immunoassay (LFIA) test for IgG¹¹, the data presented here 110 were generated using the Euroimmun® assay. The independent "REACT" study acts as a validation 111 dataset, lending credence to the seroprevalence values used. For example, seroprevalence in London 112 was reported by REACT to be 13.0% (12.3-13.6) for the period 20 June to 13 July 2020. In 113 comparison, the London blood-donor time series indicated seroprevalence to be 13.3% (8.4-16) on 114 21 June 2020. 115

We developed a method that combines daily mortality data with seroprevalence in England, using a 116 mechanistic mathematical model to infer the temporal trends of exposure and seroprevalence during 117 the COVID-19 epidemic. We fit the mathematical model jointly to serological survey data from 118 119 seven regions in England (London, North West, North East (North East and Yorkshire and the Humber regions), South East, South West, Midlands (East and West Midlands combined), and East 120 of England) using a statistical observation model. For more details on the input data sources, 121 mechanistic model and fitting procedure, see the Materials and Methods section. We considered that 122 mortality is perfectly reported and proceeded to use this anchoring variable to extrapolate the number 123 of people infected 3-weeks prior. We achieved this by estimating region-specific IFRs (defined as 124 γ_i), which we initially assumed to be time invariant, later relaxing this assumption. The 125 identifiability of the IFR metric was guaranteed by using the serological data described above as a 126 second source of information on exposure. From the moment of exposure, individuals seroconvert a 127

fixed 21 days later and can then serorevert at a rate, β , that is estimated as a global parameter. We thus have both mortality and prevalence of seropositivity informing SARS-CoV-2 exposure over time.

131

Several other research groups have used mortality data to extrapolate exposure and as a result 132 provide estimates for IFR. Some IFR estimates were published assuming serology cross-sectional 133 prevalence to be a true reflection of population exposure, while others used infection numbers 134 generated by mechanistic dynamic models fit to mortality data²¹. Most recently, sophisticated 135 statistical techniques have been used, which take into account the time lag between exposure and 136 seroconversion when estimating the underlying population exposure from seroprevalence 137 measurements²², with one study also considering seroreversion²³. Our method is very much aligned 138 with the latter but is applied at a subnational level while using a dataset that has been validated by an 139 140 independent, largely synchronous study.

141

142 **Results**

Results from the fixed IFR inference method show excellent agreement with serological data (Figure
We found that, after seroconverting, infected individuals remain seropositive for about 176 days
on average (95% CrI: 159-197) (Table 1, Table S1, and Figure 2—figure supplement 1).

146

147 **Table 1. Marginal median parameter estimates and 95% CrI for the constant IFR model.** β is 148 the rate of seroreversion and γ denotes the IFR. The estimated median time to seroreversion given 149 by $1/\beta$ is 176 (95% CrI: 159-197 days).

150

Parameters	Median (95% CrI)
β	0.0057 (0.0051 - 0.0063)
γ_{London}	0.0049 (0.0046 - 0.0063)
$\gamma_{NorthWest}$	0.0080 (0.0073 - 0.0087)
$\gamma_{NortEast}$	0.0103 (0.0095 - 0.0112)
$\gamma_{SouthWest}$	0.0094 (0.0087 - 0.0101)
$\gamma_{SouthEast}$	0.0118 (0.0109 - 0.0129)
$\gamma_{Midlands}$	0.0085 (0.0079 - 0.0091)
γ_{East}	0.0083 (0.0077 - 0.0090)

151

152 This relatively rapid (approximately six months) seroreversion is similar to other estimates from experimental studies^{13,14}, and might explain the reported 83% protection against reinfection within 6 153 months of disease in UK patients²⁴. As a consequence of this rapid seroreversion, epidemic 154 progression will result in an increasing gap between measured serology prevalence levels and 155 156 cumulative population exposure to the virus. Ultimately, this may mean that more than twice as many people have been exposed to the virus relative to the number of people who are seropositive 157 (Figure 2), raising questions about the relevance of serological data for informing policy decisions 158 159 moving forward. We also estimated age-independent IFRs for seven English regions (means ranging from 0.49% to 1.18% - Table 1) that are in very good agreement with other estimates for England²⁵. 160

161

163 Figure 2. Time course of the SARS-CoV-2 pandemic up to 7 November 2020 for seven regions

in England. The solid orange circles and black error bars in each regional panel represent the observed seroprevalence data and their confidence interval, respectively, after adjusting for the sensitivity and specificity of the antibody test. The green and orange lines show the model predictions of median exposure and seroprevalence, respectively, while the shaded areas correspond to 95% CrI. The regional predicted exposure levels (expressed as the proportion of the population that has been infected) as of 17 October 2020 are shown on the map of England.







The estimated IFRs are noticeably lower for London, which can be explained by differences in population age structure across the seven regions considered here. London has a considerably younger population than other regions of England, which, associated with increasing severity of disease with increasing age^{26,27}, results in a lower expected number of fatalities given a similar number of infections. This could be construed as a possible explanation for fluctuations in estimates of the country-wide IFR over time²⁵, as outbreaks occur intermittently across regions with different underlying IFRs. An alternative interpretation of IFR trends in England is that individuals who are

180 more likely to die from infection (due to some underlying illness or other risk factors) will do so earlier. This means that as the epidemic progresses, a selection (through infection) for a decrease in 181 average population frailty (a measure of death likelihood once infected) is taking place and, 182 consequently, a reduction in the ratio of deaths to infections. To test this hypothesis, we constructed 183 an alternative formulation of our modelling approach, whereby the IFR at a specific time is 184 dependent on the stage of epidemic progression – Figure 3. It is extremely difficult to extrapolate the 185 underlying risk of infection from reported case data due to the volatility in testing capacity. Hence, 186 we propose that the optimal metric for epidemic progression is the cumulative test positivity ratio. In 187 the absence of severe sampling biases, the test positivity ratio is a good indicator of changes in 188 underlying population infection risk, as a larger proportion of people will test positive if infection 189 prevalence increases. In fact, it is clear from (Figure 3 – figure supplement 3 that the test positivity 190 ratio is a much better indicator of exposure than the case fatality ratio (CFR) or the hospitalization 191 192 fatality ratio (HFR), since it mirrors the shape of the mortality incidence curve. For the time-varying IFR, we took the normalized cumulative test positivity ratio time series and applied it as a scalar of 193 194 the maximum IFR value estimated for each region - for more details can be found in the Materials 195 and Methods section.

196

Results from the time-varying IFR model indicate that the population of London might have undergone a significant frailty selection process during the first wave of the epidemic and now shows a significantly lower IFR compared with March/April 2020 (Figure 3 – figure supplement 2). Interestingly, no statistically significant time-dependence on IFR was inferred for any of the

remaining regions (Figure 3 – figure supplement 1), suggesting this phenomenon is dependent on age
 structure.

203

Figure 3. Time course of the SARS-Cov-2 pandemic up to 7 November 2020 for seven regions 204 205 in England for time-varying IFR model. The orange solid circles and black error bars in each regional panel represent the observed seroprevalence data and its confidence interval after adjusting 206 for the sensitivity and specificity of the antibody test. The green and orange lines show the median 207 time-varying IFR model predictions for exposure, and seroprevalence, respectively, while the shaded 208 areas correspond to 95% CrI. The regional median predicted exposure levels (expressed as the 209 proportion of the population that has been infected) as of 17 October 2020 are shown on the map of 210 211 England.

212



214

We can eliminate exposure levels as the main driver of this process as there is no clear temporal signal for IFR for the only other region (North West) with a comparable force of selection (i.e.,

similar predicted exposure levels). It seems that in younger populations, with a lower subset of very frail individuals, this selection will be more pronounced. Overall, the estimates obtained with both models are very consistent, with the estimated credible intervals for the time varying IFR model including the median estimated obtained for the fixed IFR model (Figure 3 – figure supplement 1 and Table S3).

222

223 Discussion

Given the current polarization of opinion around COVID-19 natural immunity, we realize that our 224 results are likely to be interpreted in one of two conflicting ways: (1) the rate of seroreversion is high, 225 therefore achieving population (herd) immunity is unrealistic, or (2) exposure in more affected places 226 such as London is much higher than previously thought, and population immunity has almost been 227 reached, which explains the decrease in IFR over time. We would like to dispel both interpretations 228 229 and stress that our results do not directly support either. Regarding (1), it is important to note that the rate of decline in neutralizing antibodies, reflective of the effective immunity of the individual, is not 230 the same as the rate of decline in seroprevalence. Antibodies may visibly decline in individuals yet 231 remain above the detection threshold for antibody testing⁶. Conversely, if the threshold antibody titer 232 above which a person is considered immune is greater than the diagnostic test detection limit, 233 individuals might test positive when in fact they are not effectively immune. The relationship 234 between the presence and magnitude of antibodies (and therefore seropositive status) and protective 235 immunity is still unclear, with antibodies that provide functional immunity only now being 236 discovered¹³. Furthermore, T cell mediated immunity is detectable in seronegative individuals and is 237

associated with protection against disease⁸. Therefore, the immunity profile for COVID-19 goes 238 beyond the presence of a detectable humoral response. We believe our methodology to estimate total 239 exposure levels in England offers valuable insights and a solid evaluation metric to inform future 240 health policies (including vaccination) that aim to disrupt transmission. With respect to (2), we must 241 clarify that decreasing IFR trends can result solely from selection processes operating at the 242 intersection of individual frailty and population age structure. Likewise, the lower IFR in London can 243 be attributed to its relatively younger population when compared with populations in the other 244 regions of England. In conclusion, a method that accounts for seroreversion using mortality data 245 allows the total exposure to SARS-CoV-2 to be estimated from seroprevalence data. The associated 246 estimate of time to seroreversion of 176 days (95% CrI: 159-197) lies within realistic limits derived 247 from independent sources. The total exposure in regions of England estimated using this method is 248 more than double the last seroprevalence measurements. Implications for the impact of vaccination 249 250 and other future interventions depend on the, as yet uncharacterized, relationships between exposure to the virus, seroprevalence, and population immunity. To assess vaccination population impact one 251 can consider the population at risk to be those individuals who are seronegative, those with no past 252 253 exposure (confirmed or predicted), or those with no T cell reactivity. In this manuscript, we offer an extra dimension to the evidence base for immediate decision-making, as well as anticipating future 254 information from the immunological research community about the relationship between 255 SARS-CoV-2 exposure and immunity. 256

257

258 Materials and Methods

259 Data Sources

We used publicly available epidemiological data to infer the underlying exposure to SARS-CoV-2 over time, as described below:

262

263	Regional	dailv	death
205	nezionai	aaiiy	acam

The observed daily mortality data for each of 7 English regions (London, North West, North East (contains both North East and Yorkshire and the Humber regions), South East, South West, Midlands (West and East Midlands combined) and East of England) from January 1st 2020 to November 11th 2020 relates to daily deaths with COVID-19 on the death certificate by date of death. This information was extracted from the UK government's official Covid-9 online dashboard³² on March 8, 2021.

270

271 *Regional adjusted seroprevalence*

272 Region specific SARS-CoV-2 antibody seroprevalence measurements, adjusted for the sensitivity 273 and specificity of the antibody test, were retrieved from Public Health England's National 274 COVID-19 surveillance report¹⁶.

275

276 *Regional case positivity ratios*

Weekly positivity ratios of laboratory confirmed COVID-19 cases for each of 7 English regions were obtained from the week 40 and week 45 (2020) Public Health England's National COVID-19 surveillance reports^{16, 33}. The first report contains Pillar 1 testing information spanning weeks 5 (2020)

280	to 39 (2020), and Pillar 2 positivity ratios from week 19 up to week 39 (2020). The second report
281	presents both Pillar 1 and Pillar 2 testing data from week 27 to week 44 (2020). We took the average
282	of both Pillar 1 and Pillar 2 test positivity ratios where both data were available.

283

284 *Regional population*

- Region specific population structures were obtained from the UK Office for National Statistics 2018
 population survey³⁴.
- 287

288 Mechanistic model

We developed a mechanistic mathematical model that relates reported COVID-19 daily deaths to 289 seropositive status by assuming all COVID-19 deaths are reported and estimating an infection 290 fatality ratio that is congruent with the observed seroprevalence data. For each region, i = 1, ..., 7291 292 corresponding to London, North West, North East, South East, South West, Midlands and East of England respectively, we denote the infection fatality ratio at time t by $\alpha_i(t)$ and the number of 293 daily deaths by $m_i(t)$. While we formulate the model in terms of a general, time-dependent, infection 294 fatality ratio, we assume its default shape to be time invariant and later allow infection fatality ratio 295 to vary with the stage of the epidemic. 296

Using the diagram in Figure 1 as reference, and given a number of observed deaths at time t, $m_i(t)$, we can expect a number of infections $\frac{1}{\alpha_i(t)}m_i(t)$ to have occurred d_e days before. Of these infected individuals, $m_i(t)$ will eventually die, whilst the remaining $\frac{1-\alpha_i(t)}{\alpha_i(t)}m_i(t)$ will seroconvert from

300 sero-negative to sero-positive. This assumes that seroconversion happens, on average, with the same301 delay from the moment of infection as death.

302 Assuming that seropositive individuals convert to seronegative (serorevert) at a rate β , the rate of 303 change of the number of seropositive individuals in region *i*, $X_i(t)$, is given by:

$$\frac{dX_i}{dt} = \frac{1 - \alpha_i(t)}{\alpha_i(t)} m_i(t) - \beta X_i \tag{1}$$

Solving Equation (1), subject to the initial condition $X_i(t_0) = 0$ where t is time since January 1st, 2020, gives:

307
$$X_{i}(t) = e^{-\beta t} \int_{t_{0}}^{t} e^{\beta w} \frac{(1-\alpha_{i}(w))}{\alpha_{i}(w)} m_{i}(w) dw$$
(2)

308 Discretizing Equation (2) with daily intervals ($\Delta w = 1$) gives:

309
$$X_{i}(t) = e^{-\beta t} \sum_{w=t_{0}}^{t} \left[\frac{(1-\alpha_{i}(w))}{\alpha_{i}(w)} e^{\beta w} m_{i}(w) \right]$$
(3)

The model-predicted proportion of seropositive individuals in each population, $x_i(t)$, is calculated by dividing $X_i(t)$ (Equation (3)) by the respective region population size at time t, $P_i - \sum_{w=t_0}^{t} m_i(w)$, where P_i is the reported population in region i before the COVID-19 outbreak³⁴:

313
$$x_{i}(t) = e^{-\beta t} \left[P_{i} - \sum_{w=t_{0}}^{t} m_{i}(t) \right]^{-1} \sum_{w=t_{0}}^{t} \left[\frac{(1 - \alpha_{i}(w))}{\alpha_{i}(w)} e^{\beta w} m_{i}(w) \right]$$
(4)

This is relatively straightforward when the serology data is already adjusted for test sensitivity and specificity as is the case. For unadjusted antibody test results, the proportion of the population that would test positive given the specificity (k_{sp}) and sensitivity (k_{se}) can be calculated as

317
$$z_i(t) = k_{se} x_i(t) + (1 - k_{sp})(1 - x_i(t))$$

318 As mentioned earlier, the method that we present in this paper allows for the infection fatality ratio,

319 $\alpha_i(t)$, to be (a) constant or (b) vary over time with the stage of the epidemic:

320 (a) For constant infection fatality ratio, we have:

$$\alpha_i(t) = \gamma_i$$

321 (b) For time-varying infection fatality ratio, we first define the epidemic stage, ES(t), as the 322 normalized cumulative positivity ratio:

323

$$ES_i(t) = \frac{\sum_{t=t_0}^t y_i(t-\delta_p)}{\sum_{t=t_0}^T y_i(t-\delta_p)}$$
(5)

where $y_i(t)$ is the confirmed case positivity ratio at time t in the proportion of individuals testing positive for the virus, δ_p is the average time between testing positive and seroconversion (see Figure 1) and T is the total number of days from t_0 until the last date of positivity data. In this work, we fixed $\delta_p = 7$ days (see Figure 1 and main text). We assume that the infection fatality ratio is a linear function of the normalized cumulative positivity ratio as follows:

$$\alpha_i(t) = \gamma_i(1 - \eta_i)ES_i(t) \tag{6}$$

where $\eta_i \in [0,1]$ and $\gamma_i \in [0,1]$ are coefficients to be estimated. At the start of the epidemic when epidemic stage is 0 (see Equation (5)), then $\alpha_i(t) = \gamma_i$, whereas when epidemic stage is 1,

333 $\alpha_i(t) = \gamma_i - \eta_i \times \gamma_i \leq \gamma_i$.

In Equation (5), $y_i(t)$ is taken from the regional weekly test positivity ratios (see Data section),

converted to daily positivity ratios (taken to be the same over the week).

336

Once the model is parameterized, we can estimate the total proportion of the population that has been exposed, E_i , with the following formula:

339
$$E_i(t - \delta_{\epsilon}) = \left[P_i - \sum_{w=t_0}^t m(w)\right]^{-1} \sum_{w=t_0}^t \frac{1 - \alpha_i(w)}{\alpha_i(w)} m_i(w)$$
(7)

340 where δ_{ϵ} is fixed to 21 days (Figure 1).

341

342 Observation model for statistical estimation of model parameters

We developed a hierarchical Bayesian model to estimate the model parameters θ , and present the posterior predictive distribution of the seroprevalence (Equation (4)) and exposure (Equation (7)) over time. Results are presented as the median of the posterior with the associated 95% credible intervals (CrI). We assumed a negative binomial distribution³⁵ for the observed number of seropositive individuals in region *i* over time, $X_i^{obs}(t)$:

348
$$X_i^{obs}(t) = x_i^{obs}(t) \times \left(P_i - \sum_{w=t_0}^t m_i(w)\right)$$
(8)

where $x_i^{obs}(t)$ is the observed seroprevalence in region *i* over time. Then the observational model is specified for region *i* with observations at times $t_{i1}, t_{i2} \dots, t_{in_i}$:

351
$$X_i^{obs}(t) \sim NB(X_i(t), \phi), \quad t = t_{i1}, t_{i2} \dots, t_{in_i}$$
(9)

where $NB(X_i(t), \phi)$ is a negative binomial distribution, with mean $X_i(t)$ – given by equation (3)– and ϕ is an overdispersion parameter. We set ϕ to 100 to capture additional uncertainty in data points that would not be captured with a Poisson or binomial distribution. We assume uninformative beta priors for each of the parameters, according to the assumption made for how the infection fatality ratio is allowed to vary over time:

- 357 (a) For constant infection fatality ratio, we have $\theta = \{\{\gamma_i\}_{i=1}^{i=7}, \beta\}$ and take priors:
- 358 $\gamma_i \sim Beta(1,1), \ \beta \sim Beta(1,1)$ (10)

359 (b) For time-varying infection fatality ratio, we have $\theta = \{\{\gamma_i\}_{i=1}^{i=7}, \{\eta_i\}_{i=1}^{i=7}, \beta\}$ and take priors:

360
$$\gamma_i \sim Beta(1,1), \quad \eta_i \sim Beta(1,1), \quad \beta \sim Beta(1,1)$$
 (11)

We use Bayesian inference (Hamiltonian Monte Carlo algorithm) in RStan³⁶ to fit the model to 361 seroprevalence data by running four chains of 20,000 iterations each (burn-in of 10,000). We use 362 2.5% and 97.5% percentiles from the resulting posterior distributions for 95% CrI for the parameters. 363 The Gelman-Rubin diagnostics (\hat{R}) given in Table S1 and Table S 364 2 show values of 1, indicating that there is no evidence of non-convergence for either model 365 formulation. Furthermore, the effective sample sizes (n_{eff}) in Table S1 and Table S2 are all more 366 than 10,000, meaning that there are many samples in the posterior that can be considered 367 independent draws. 368 369 Acknowledgments: We would like to thank Adam Bodley for scientific writing assistance 370 (according to Good Publication Practice guidelines) and editorial support. JF acknowledges funding 371 from the Australian Research Council (DP200100747). LJW is funded by the Li Ka Shing 372 373 Foundation, and the University of Oxford's COVID-19 Research Response Fund (BRD00230). RA is funded by the Bill and Melinda Gates Foundation (OPP1193472). 374

375

Author contributions: LJW and RA conceptualized the analysis; SC curated and formatted the data
for analysis; SC and JAF developed the statistical model and performed the Bayesian inferences;
LJW and RA wrote the first draft. SC, JAF, LJW and RA reviewed the results and edited the
manuscript.

380

381 **Competing interests:** Authors declare no competing interests.

3	82

383	Da	ta and materials availability: All data, code, and materials used in the analyses can be accessed
384	at:	https://github.com/SiyuChenOxf/COVID19SeroModel/tree/master. All parameter estimates and
385	fig	ures presented can be reproduced using the codes provided. This work is licensed under a Creative
386	Co	mmons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use,
387	dis	tribution, and reproduction in any medium, provided the original work is properly cited.
388		
389	Re	ferences
390	1.	Nicola, Maria, Zaid Alsafi, Catrin Sohrabi, Ahmed Kerwan, Ahmed Al-Jabir, Christos Iosifidis,
391		Maliha Agha, and Riaz Agha. "The socio-economic implications of the coronavirus and
392		COVID-19 pandemic: a review." International journal of surgery (2020). DOI:
393		https://doi.org/10.1016/j.ijsu.2020.04.018
394	2.	Mahdi, A., Blaszczyk, P., Dlotko, P., Salvi, D., Chan, T.S.T., Harvey, J., Gurnari, D., Wu, Y.,
395		Farhat, A., Hellmer, N. and Zarebski, A.E., 2020. OxCOVID19 Database: a multimodal data
396		repository for better understanding the global impact of COVID-19. medRxiv.
397	3.	Metcalf, C.J.E., Viboud, C., Spiro, D.J. and Grenfell, B.T., 2020. Using Serology with Models to
398		Clarify the Trajectory of the SARS-CoV-2 Emerging Outbreak. Trends in Immunology, 41(10),
399		pp.849-851. DOI: https://doi.org/10.1016/j.it.2020.06.011
400	4.	Watson, J., Richter, A. and Deeks, J., 2020. Testing for SARS-CoV-2 antibodies. bmj, 370. DOI:
401		https://doi.org/10.1136/bmj.m3325

- 402 5. Ibarrondo, F.J., Fulcher, J.A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M.A.,
- 403 Ferbas, K.G., Tobin, N.H., Aldrovandi, G.M. and Yang, O.O., 2020. Rapid decay of
- 404 anti–SARS-CoV-2 antibodies in persons with mild Covid-19. New England Journal of Medicine,
- 405 383(11), pp.1085-1087. DOI: 10.1056/NEJMc2025179
- 406 6. Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K.J., Hemmings, O., O'Bryne, A., Kouphou,
- 407 N., Pickering, S., Galao, R. and Betancor, G., 2020. Longitudinal evaluation and decline of
- 408 antibody responses in SARS-CoV-2 infection. MedRxiv. Preprint at
- 409 https://medrxiv.org/content/10.1101/2020.07.09.20148429v1.full.
- 410 7. Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y.,
- 411 Cai, X.F. and Wang, D.Q., 2020. Antibody responses to SARS-CoV-2 in patients with
- 412 COVID-19. Nature medicine, 26(6), pp.845-848. DOI:
- 413 https://doi.org/10.1038/s41591-020-0897-1
- 414 8. Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.B., Olsson, A.,
- Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S. and Wullimann, D.J., 2020.
- 416 Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell,
- 417 183(1), pp.158-168. DOI: https://doi.org/10.1016/j.cell.2020.08.017
- 418 9. Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
- 419 S.A., Sutherland, A., Premkumar, L., Jadi, R.S. and Marrama, D., 2020. Targets of T cell
- 420 responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed
- 421 individuals. Cell, 181(7), pp.1489-1501. DOI: https://doi.org/10.1016/j.cell.2020.05.015

- 422 10. Arora, R.K., Joseph, A., Van Wyk, J., Rocco, S., Atmaja, A., May, E., Yan, T., Bobrovitz, N.,
- 423 Chevrier, J., Cheng, M.P. and Williamson, T., 2020. SeroTracker: a global SARS-CoV-2
- 424 seroprevalence dashboard. The Lancet. Infectious Diseases. DOI:
- 425 10.1016/S1473-3099(20)30631-9
- 426 11. Ward, H., Atchison, C.J., Whitaker, M., Ainslie, K.E., Elliot, J., Okell, L.C., Redd, R., Ashby,
- 427 D., Donnelly, C.A., Barclay, W. and Darzi, A., 2020. Antibody prevalence for SARS-CoV-2 in
- 428 England following first peak of the pandemic: REACT2 study in 100,000 adults. MedRxiv.
- 429 Preprint at https:// medrxiv.org/content/10.1101/2020.08.12.20173690v1 (2020).
- 430 12. Burgess, S., Ponsford, M.J. and Gill, D., 2020. Are we underestimating seroprevalence of
- 431 SARS-CoV-2? DOI: https://doi.org/10.1136/bmj.m3364
- 432 13. Ripperger, T.J., Uhrlaub, J.L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H.A.,
- 433 Thompson, M.R., Bradshaw, C., Weinkauf, C.C., Bime, C. and Erickson, H.L., 2020.
- 434 Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities
- and reveal durable humoral immunity. Immunity, 53(5), pp.925-933. DOI:
- 436 https://doi.org/10.1016/j.immuni.2020.10.004
- 437 14. Iyer, A.S., Jones, F.K., Nodoushani, A., Kelly, M., Becker, M., Slater, D., Mills, R., Teng, E.,
- 438 Kamruzzaman, M., Garcia-Beltran, W.F. and Astudillo, M., 2020. Persistence and decay of
- 439 human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in
- 440 COVID-19 patients. Science immunology, 5(52). DOI: 10.1126/sciimmunol.abe0367
- 441 15. Ward, H., Cooke, G., Atchison, C.J., Whitaker, M., Elliott, J., Moshe, M., Brown, J.C., Flower,
- 442 B., Daunt, A., Ainslie, K.E. and Ashby, D., 2020. Declining prevalence of antibody positivity to

443	SARS-CoV-2: a commu	inity study	of 365.000 adults.	MedRxiv. Preprint at

- 444 https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.
- 16. Public Health England, "National COVID-19 surveillance reports" (2020).
- 446 https://www.gov.uk/government/publications/national-covid-19-surveillance-reports
- 447 17. Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S.A., Zhang, T.
- 448 and Gao, W., 2020. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their
- 449 close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases,
- 450 20(8), pp.911-919.DOI: https://doi.org/10.1016/S1473-3099(20)30287-5
- 451 18. Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg,
- 452 G., Thompson, H., Walker, P.G., Fu, H. and Dighe, A., 2020. Estimates of the severity of
- 453 coronavirus disease 2019: a model-based analysis. The Lancet infectious diseases, 20(6),

454 pp.669-677.DOI: https://doi.org/10.1016/S1473-3099(20)30243-7

- 455 19. Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J. and
- 456 Qian, S., 2020. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease
- 457 2019. Clinical infectious diseases, 71(16), pp.2027-2034. DOI:
- 458 https://doi.org/10.1093/cid/ciaa344
- 459 20. Nicol, T., Lefeuvre, C., Serri, O., Pivert, A., Joubaud, F., Dubée, V., Kouatchet, A., Ducancelle,
- 460 A., Lunel-Fabiani, F. and Le Guillou-Guillemette, H., 2020. Assessment of SARS-CoV-2
- serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays:
- 462 Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow

- 463 immunoassay (NG Biotech). Journal of Clinical Virology, 129, p.104511.DOI:
- 464 https://doi.org/10.1016/j.jcv.2020.104511
- 465 21. Meyerowitz-Katz, G. and Merone, L., 2020. A systematic review and meta-analysis of published
- 466 research data on COVID-19 infection-fatality rates. International Journal of Infectious Diseases.
- 467 DOI: https://doi.org/10.1016/j.ijid.2020.09.1464
- 468 22. Stringhini, S., Wisniak, A., Piumatti, G., Azman, A.S., Lauer, S.A., Baysson, H., De Ridder, D.,
- 469 Petrovic, D., Schrempft, S., Marcus, K. and Yerly, S., 2020. Seroprevalence of
- 470 anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based
- 471 study. The Lancet, 396(10247), pp.313-319. DOI:
- 472 https://doi.org/10.1016/S0140-6736(20)31304-0
- 473 23. Brazeau, N., Verity, R., Jenks, S., Fu, H., Whittaker, C., Winskill, P., Dorigatti, I., Walker, P.,
- 474 Riley, S., Schnekenberg, R.P. and Heltgebaum, H., 2020. Report 34: COVID-19 infection
- fatality ratio: estimates from seroprevalence. DOI: https://doi.org/10.25561/83545
- 476 24. Hall, V. et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates
- than antibody negative healthcare workers? Large multi-centre prospective cohort study (the
- 478 SIREN study), England: June to November 2020. Preprint at
- 479 https://www.medrxiv.org/content/10.1101/2021.01.13.21249642v1.full-text (2021).
- 480 25. Howdon, D., Oke, J. & Heneghan, C. Estimating the infection fatality ratio in England. The
- 481 *Centre for Evidence-Based Medicine.*
- 482 https://www.cebm.net/covid-19/estimating-the-infection-fatality-ratio-in-england/ (2020)

- 483 26. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X. and
- 484 Guan, L., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19
- in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), pp.1054-1062. DOI:
- 486 https://doi.org/10.1016/S0140-6736(20)30566-3
- 487 27. Davies, N.G., Klepac, P., Liu, Y., Prem, K., Jit, M. and Eggo, R.M., 2020. Age-dependent
- 488 effects in the transmission and control of COVID-19 epidemics. Nature medicine, 26(8),
- 489 pp.1205-1211. DOI: https://doi.org/10.1038/s41591-020-0962-9
- 490 28. Salje, H., Kiem, C.T., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé,
- 491 N., Richet, J., Dubost, C.L. and Le Strat, Y., 2020. Estimating the burden of SARS-CoV-2 in

492 France. Science, 369(6500), pp.208-211.DOI: 10.1126/science.abc3517

- 493 29. Office for National Statistics. 2019 Datasets: Population estimates local authority based by
 494 single year of age. Available from:
- 495 https://www.nomisweb.co.uk/query/construct/submit.asp?forward=yes&menuopt=201&subcom
 496 p=
- 497 30. e Silva, L.V., de Andrade Abi, M.D.P., Dos Santos, A.M.T.B., de Mattos Teixeira, C.A., Gomes,
- 498 V.H.M., Cardoso, E.H.S., da Silva, M.S., Vijaykumar, N.L., Carvalho, S.V. and Frances, C.R.L.,
- 499 2020. COVID-19 mortality underreporting in Brazil: analysis of data from government internet
- 500 portals. Journal of Medical Internet Research, 22(8), p.e21413. DOI: 10.2196/21413
- 501 31. Chatterjee, P., 2020. Is India missing COVID-19 deaths?. The Lancet, 396(10252), p.657. DOI:
- 502 https://doi.org/10.1016/S0140-6736(20)31857-2

- 503 32. The official UK Government website for data and insights on Coronavirus (COVID-19). Public
- 504 Health England and NHSX. https://coronavirus.data.gov.uk/ (2020).
- 505 33. National flu and COVID-19 surveillance report (week 45). Public Health England.
- 506 https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports (2020).
- 507 34. Population age structure by single year of age and sex for local authorities, counties, regions and
- 508 England as a whole, mid-2018 to mid-2043. Office for National Statistics.
- https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationesti
 mates/articles/ukpopulationpyramidinteractive/2020-01-08 (2020).
- 511 35. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. and Wiersma, S.T., 2013. Global epidemiology
- of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence.
- 513 Hepatology, 57(4), pp.1333-1342. DOI: https://doi.org/10.1002/hep.26141
- 514 36. Stan Development Team, RStan: The R interface to Stan. https://mc-stan.org/ (2020).

- Figure 2 figure supplement 1. Marginal posterior distributions for parameters in the 516
- constant infection fatality ratio model. Vertical lines show median of distribution and grey shaded 517
- region shows 95% CrI. 518
- 519

Posterior distributions



- 521 Figure 3 — figure supplement 1. Marginal posterior distributions for parameters in the
- time-varying infection fatality ratio model. Vertical lines show median of distribution and grey 522
- shaded region shows 95% CrI. 523
- 524



526 Figure 3 - figure supplement 2. Posterior predictive distribution of time-varying infection



fatality ratio. Solid line shows median and shaded region 95% CrI. 527

Figure 3 — figure supplement 3. Relevant epidemiological metrics in England over the course of the pandemic. Top subplot shows COVID-19 cases and deaths (yellow and blue lines, respectively) per 100,000 population in England from Feb 5 2020 to Nov 7, 2020. Bottom subplot shows the normalized case fatality rate, hospital fatality rate and virus positivity (yellow, blue, and green lines, respectively). We assumed fixed time lags of $\delta_p = 14$ days between PCR testing and death and $\delta_h = 12$ days between PCR testing and hospitalization.



- 536 **Table S1.** The effective sample size (n_{eff}) and the Gelman-Rubin diagnostic (\widehat{R}) for the 8 model
- 537 parameters in the default model (constant infection fatality ratio).

538

Parameter	n _{eff}	R
β	12410	1
γ_{London}	18054	1
$\gamma_{NorthEast}$	29625	1
$\gamma_{SouthEast}$	23952	1
$\gamma_{NorthWest}$	28611	1
$\gamma_{SouthWest}$	22006	1
ΥMidlands	21334	1
γ_{East}	20992	1

- 540 **Table S2.** The effective sample size (n_{eff}) and the Gelman-Rubin diagnostic (\widehat{R}) for the 15 model
- 541 parameters in the time-varying infection fatality ratio model.
- 542

Parameter	n _{eff}	R
β	35229	1
γ_{London}	32184	1
η_{London}	26680	1
$\gamma_{NorthEast}$	38159	1
$\eta_{NorthEast}$	33166	1
$\gamma_{SouthEast}$	24036	1
$\eta_{SouthEast}$	24430	1
$\gamma_{NorthWest}$	32887	1
$\eta_{\textit{NorthWest}}$	29965	1
$\gamma_{SouthWest}$	24430	1
$\eta_{SouthWest}$	31047	1
$\gamma_{Midlands}$	31943	1
$\eta_{Midlands}$	27558	1
γ_{East}	24703	1
η_{East}	25506	1

Table S3. Marginal median parameter estimates and 95% CrI for the time-varying infection fatality
 ratio model.

546

Parameter	Median (95%CrI)
β	0.0061 (0.0054 - 0.0068)
γ_{London}	0.0054 (0.0048- 0.0063)
η_{London}	0.30 (0.26 - 0.60)
$\gamma_{NorthEast}$	0.011 (0.0095 - 0.012)
$\eta_{NorthEast}$	0.077 (0.0029 - 0.33)
$\gamma_{NorthWest}$	0.0083 (0.0074 - 0.0098)
$\eta_{NorthWest}$	0.15 (0.0069 - 0.51)
$\gamma_{SouthWest}$	0.0094 (0.0086 - 0.011)
$\eta_{SouthWest}$	0.060 (0.0021- 0.26)
$\gamma_{SouthEast}$	0.0013 (0.011 - 0.017)
$\eta_{SouthEast}$	0.17 (0.0070 - 0.53)
γMidlands	0.0088 (0.0079- 0.010)
$\eta_{Midlands}$	0.14 (0.0060 - 0.42)
γ_{East}	0.0089 (0.0077 - 0.012)
η_{East}	0.18 (0.0080 - 0.57)